Arrowhead Pharmaceuticals (ARWR) Total Current Liabilities (2010 - 2026)

Arrowhead Pharmaceuticals (ARWR) has 17 years of Total Current Liabilities data on file, last reported at $295.2 million in Q1 2026.

• Quarterly Total Current Liabilities rose 33.86% year-over-year to $295.2 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $295.2 million (up 33.86% YoY) and the FY2025 annual result came in at $195.5 million, up 89.48% from the prior year.
• Total Current Liabilities slipped to $295.2 million in Q1 2026, from $347.4 million in the prior quarter.
• In the past five years, Total Current Liabilities ranged from a high of $347.4 million in Q4 2025 to a low of $63.7 million in Q4 2023.
• A 5-year average of $145.1 million and a median of $122.0 million in 2022 frame the typical range for Total Current Liabilities.
• Annual changes were most pronounced in 2023 — Total Current Liabilities tumbled 47.77% — and 2025, when it surged 270.56%.
• Tracing ARWR's Total Current Liabilities over 5 years: stood at $122.0 million in 2022, then slumped by 47.77% to $63.7 million in 2023, then soared by 47.13% to $93.8 million in 2024, then surged by 270.56% to $347.4 million in 2025, then declined by 15.03% to $295.2 million in 2026.
• The last three Total Current Liabilities figures came in at $295.2 million (Q1 2026), $347.4 million (Q4 2025), and $195.5 million (Q3 2025), per Business Quant data.